Map pointer

3855 SW 153rd Drive, Beaverton, Oregon 97003

Email icon

Membership Overview

  • Members of the Subcutaneous Drug Development and Delivery (SC) Consortium are a diverse set of stakeholders, who come from organizations varying in size and background. Organizations eligible for membership include: small and large biotech companies, non-profit organizations, academics, payers, and regulatory agencies.
  • The collective objective of members is to collaboratively advance the most pressing issues and opportunities in subcutaneous drug development and delivery in a precompetitive manner.

Membership Benefits

Tiered Membership Structure

The Subcutaneous Drug Development and Delivery (SC) Consortium features a tiered membership structure, designed to promote participation tailored to the specific organization’s interest levels. The variety of membership options gives your company the flexibility to choose your level of engagement based on your technology interests and priorities.

  • Tier 1 member organizations are part of the Governing Board, which lead the strategic direction of the Consortium.
  • Tier 2 members take part in specific sub-teams and work towards sub-team specific problem statements.

Please find an overview of the membership structure in the table below.

Tier 1 – Governing Board Members

Membership Rights

  • Automatic/designated primary and supporting board seat
  • Full voting rights on Governing Board
  • Can lead sub-teams
  • Participation of as many members as wanted in any sub-teams

Annual Dues

$50,000 USD

Tier 2 – Sub-Team Collaborators

Membership Rights

  • Participation on any/all sub-teams and ability to influence direction of sub-team work
  • Must comply with all legal/membership obligations of the SC Consortium (IPR, anti-competitive policy, etc.)
  • Non-voting participation on the Board and Sub-Teams

Annual Dues

Industry

  • Company Revenue >$500M = $35,000 USD
  • Company Revenue < $500M = $15,000 USD

Non-Industry

  • Regulatory agencies, Payers, PAGs, and Academic Institutions = $1,000 USD

The Subcutaneous Drug Development and Delivery (SC) Consortium has no organization eligibility requirements – any type of organization can join as a Tier 1 or 2 Member.

Empower innovations, join us to shape the future of subcutaneous drug development together!

Frequently Asked Questions (FAQs)

The Subcutaneous Drug Development and Delivery (SC) Consortium, herein SC Consortium, currently comprises six sub-teams, each working towards their own problem statements and research goals within the field:

  • High-Dose/High-Volume
  • Patient Preference and Experience
  • Clinical Trial Strategy
  • Bioavailability
  • Immunogenicity
  • Sustainability

Member organizations are allowed to change their tier of membership at any point in time. An organization that changes their membership tier is responsible for prorated dues for the remainder of the calendar year in order to serve as a Governing Board (Tier 1) member.

Tier 2 membership enables your organization to join as many sub-teams of interest.

Tier 1 members participate in bi-monthly Governing Board meetings, which is primarily held in virtual format with plans for occasional in-person meetings to discuss the strategic direction and ongoing activities of the Consortium.

Sub-teams have standing meetings at their own cadence for routine check-ins. These check-in meetings ensure each sub-team is actively making progress towards their planned activities and engagements, which revolve around their respective sub-team problem statements.

Tier 2 members routinely interact with Tier 1 members in all sub-team activities, in which all Governing Board members are active participants of the Consortium’s sub-teams. Sub-team activities do not distinguish membership tier with regards to participation on sub-team activities and all sub-team members work in tandem towards making progress on research problem statements.

In an effort, to advance the field of subcutaneous drug development and delivery, the Governing Board plans the strategic direction and research roadmap for sub-team activities at the beginning of each calendar year. Prior examples of sub-team activities that aim to address sub-team-specific problem statements include: landscape assessment, landscape monitoring, data synthesis, web scraping, scientific conference workshops, manuscript development and publication, quantitative and qualitative market research, etc.

Participating in the Consortium

The activities and efforts of the Subcutaneous Drug Development and Delivery Consortium provide an opportunity for participating organizations to proactively impact and drive value across SC drug development and delivery and ultimately provide value to the larger community.

SC Consortium Officers:

Donna French, PhD

President

Sachin Mittal, PhD

Vice President

Monica Adams, PhD

Marketing Officer

David Kang, PhD

Treasurer

SC Consortium: Tier 1 Members

BMS TIER 1

SC Consortium: Tier 2 Members

Koru
Nemera

SC Consortium: Governing Board/Tier 1 Members

PFIZER

Executive Director – Drug Product Design & Development

Head – Nanoparticle Development

ROCHE

Global Head Product Optimiatzation

SC Consortium CDRS Co-lead

HALOZYME

Associate Director, Drug Delivery
SC Consortium Treasurer

ASTRA ZENECA

Vice President, Dosage Form Design & Development
SC Consortium President

ASTRA ZENECA

 

Senior Director,  Astra Zeneca

SC Consortium Sustainability Co-lead

SANOFI

Global Head of Device Development Portfolio

YPSOMED

Vice President

Head of Account and Business Development

BOEHRINGER INGELHEIM

Head

Scientific Excellence and Engagement Development

The SC Consortium has been proudly engaging with Charles Rivers Associates since its inception in 2018

Robert Broadnax
NJ

Vice President

PROJECT LEAD
Brian Carpenter
NJ

Principal

PROJECT LEAD
Tyler Distefano
NY

Senior Associate

ENGAGEMENT MANAGER
Nick Wechter
SF

Consulting Associate

PROJECT SUPPORT
Sana Singru
SF

Analyst

PROJECT SUPPORT
en_USEnglish